Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02961283 · ClinicalTrials.gov registry record · Phase 1
Study of ASN003 in Subjects With Advanced Solid Tumors
A Phase 1 study, sponsored by Asana BioSciences.
- Terminated
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02961283: Clinical Trial Phase 1 study, sponsored by Asana BioSciences.
NCT02961283 is a Phase 1 study that was terminated before completion, run by Asana BioSciences. The registered enrollment target is 24 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02961283, a Phase 1 study, was terminated before completion, sponsored by Asana BioSciences.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups. The second part of the study will test how well ASN003 can control cancer. Subjects will be enrolled into one of three groups. Group 1: metastatic or recurrent melanoma with documented BRAFV600 mutation (n=20 evaluable patients) Group 2: metastatic colorectal cancer (CRC), or advanced non-small cell lung cancer (NSCLC) with documented BRAFV600 mutation (n=14 evaluable patients) Group 3: advanced solid tumors with documented PI3K pathway alterations (PIK3CA mutation or PTEN loss) (n=14 evaluable patients)
Primary Outcome
The MTD will be determined by evaluating the number of subjects with treatment related dose limiting toxicity. This is the primary endpoint of Part A
Interventions
- DRUG ASN003 ascending doses
- DRUG ASN003 MTD
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2016-10 |
| Est. Completion | 2019-02 |
| Phase | Phase 1 |
Why NCT02961283 stopped before completion
NCT02961283 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (60% lower).
The record links to 0 conditions, and to 2 interventions - of which ASN003 ascending doses is the first listed.
NCT02961283 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02961283 about?
NCT02961283 is a clinical study titled "Study of ASN003 in Subjects With Advanced Solid Tumors". The study is divided into two parts. The first part of the study will test various doses of ASN003 to find out the highest safe dose to test in three specific groups. The second part of the study will test how well ASN003 can control cancer. Subjects will be enrolled into one of three groups. Grou...
What is the current status of trial NCT02961283?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2016-10. Estimated completion is 2019-02.
What interventions are being tested in trial NCT02961283?
The interventions under investigation include: ASN003 ascending doses (DRUG), ASN003 MTD (DRUG).
Who is sponsoring clinical trial NCT02961283?
This trial is sponsored by Asana BioSciences, which has 11 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02961283's enrollment target sits among peer trials
24 1520th of 2000 higher than 405 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02331979 · 24 participants · NA
Improving Bladder Function in SCI by Neuromodulation
- NCT03096197 · 24 participants · NA
Exoskeleton and Spinal Cord Stimulation for SCI
- NCT03223922 · 24 participants · NA
Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases
- NCT03326921 · 24 participants · Phase 1
HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia